Background: In India, Breast cancer is the most common cancer in female and hormone receptor status is an important prognostic and therapeutic tool in the management of breast cancer. So this study was done with the aim to evaluate the hormone receptor status in patients with operable breast cancer at a Regional Cancer Centre in Northeast India. Methodology: This study is a retrospective case series study on 180 cases of operable breast cancer who were registered at Regional Cancer Centre, Regional Institute of Medical Sciences (RIMS), Manipur State after histopathological confirmation during the period from September 2015 to August 2018 and patients were reviewed for age, tumour size and metastatic lymph nodes positivity, histopathology, grading, hormone receptor status, staging and menstrual status. Results: Overall 180 patients was studied and evaluated for hormone receptor status. 90 cases (50.0%) were both ER-/PR-, 66 cases (36.7%) were both ER+/PR+, 14 cases (7.8%) were ER+ and 10 other cases (5.5%) were only PR+. The mean age of presentation was 52.6 ± 0.82 yrs and the number of patients reaches a peak between 31 -50 years (59.4%). Maximum patients were found to be in poor socio-economic class. Invasive duct carcinoma (96.1%) was predominant histology. Majority of the cases (84.5%) had grade-III tumour. 17.8% of total patients presented in In Northeast India, incidence rate of breast cancer among younger age group has been increasing and more patients were ER/PR negative. Maximum numbers of grade-III tumour were found to be ER/PR negative and as the tumour size increased, ER/PR negativity also increased.

Primary Bone Lymphoma (PBL) is a subtype of lymphoma that exclusively affects the skeletal tissue.Primary Bone Diffuse Large B Cell Lymphoma (DLBCL) is the most common pathological type, comprising about 80% of PBL. In this case report, we discuss a patient, a 50-year-old lady who presented with solitary bone lesion, confirmed by biopsy and IHC as DLBCL. She was diagnosed as stage IAE as per WHO staging system. Chemotherapy with R-CHOP for a total of 6 cycles were given followed by IFRT. The patient is under follow up with complete response at present. Being rare case, no randomised study can be taken up for standard treatment protocol. Case to case individualised treatment is done based on stage, histopathological subtype and predictive biomarkers to response. PBL is more common in paediatric population more than the adults.The prevalence of PBL is estimated to be 3-7% amongst all lymphomas in adults.1 WHO classification of soft tissues and bone tumors defined PBL as either single osseous lesions without regional Lymph node involvement , or tumor involvement of multiple osseous sites without associated visceral or Lymph Node disease.2